Core Viewpoint - Zhifei Biological's subsidiary, Anhui Zhifei Longkema, has successfully developed and received approval for a quadrivalent influenza virus split vaccine, marking a significant advancement in the company's product offerings [1] Group 1: Product Development and Approval - The quadrivalent influenza vaccine has been granted the "Biological Product Batch Release Certificate" by the National Medical Products Administration, allowing it to enter the market [1] - The time taken from approval to obtaining the batch release certificate was only 4 months, indicating an efficient regulatory process [1] - The vaccine has received market access in 9 provinces, including Anhui, Zhejiang, and Jiangsu [1] Group 2: Intellectual Property Advancements - Zhifei Biological has recently obtained new invention patent authorizations, including a "template DNA molecule and its application in mRNA and vaccine preparation" and a "recombinant adenovirus vaccine for varicella-zoster virus infection" [1] - Both patents have been granted by the Chinese patent office, enhancing the company's intellectual property portfolio [1]